Blue Earth Diagnostics: against COVID-19 Company
Entity: Blue Earth Diagnostics
Category: Test Kits
Description: Blue Earth Diagnostics mission is to transform the clinical management of recurrent prostate cancer. Blue Earth Diagnostics to develop and commercialise molecular imaging agents addressing areas of high un-met medical need. The company is named after Blue Earth County, Minnesota where Sir Henry Wellcome (1853-1936), the founder of the Wellcome Trust, spent his childhood. Wellcome was one of the most fascinating men of his time. A businessman, collector and philanthropist, he was born in the American Wild West but ended his days as a knight of the British Realm. He co-founded a multinational pharmaceutical company that mastered modern techniques of advertising such as promotion, image and branding. He also funded pioneering medical research, in his lifetime, scientists funded by Wellcome made great breakthroughs into understanding how our bodies work. After his death the great man’s will provided for the creation of the Wellcome Trust, whose venture investment arm Syncona Partners LLP (“Syncona”) are the founding investors in BED.
Project: UK Rapid Test Consortium (UK-RTC) for COVID-19
Summary: Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, announced that its CEO, Dr Jonathan Allis, has been appointed as Chair of the UK Rapid Test Consortium (UK-RTC) for COVID-19 by the UK Department of Health and Social Care (DHSC).
